July 30, 2014 Following up on the discovery of a new genetic mutation for MPNs, several institutions now have CALR diagnostic tests available, including the BloodCenter of Wisconsin. Click here to read the full article. Read more about the CALR discovery
July 29, 2014 The Agency for Toxic Substances and Disease Registry (ATSDR) recently released more data following their study of a Polycythemia Vera cluster that was found in the Tri-County area in Pennsylvania. Click here to read the report. More information on the PV cluster: Questions remain on the PV cluster (May 2011)Report on community screening (May 2010)Latest… Read More »2014 ATSDR ANNOUNCES MORE FINDINGS FROM PV CLUSTER IN PENNSYLVANIA
John Crispino, PhD, Scientific Advisor If it’s summer, it’s time for two important meetings where researchers present their latest findings on MPNs: In the US, it’s the American Society of Clinical Oncology (ASCO) meeting, and in Europe it’s the European Hematology Association Meeting (EHA). Here’s a brief summary of key findings: PRM-151 shows promising results… Read More »2014 SUMMER SCIENCE UPDATE
July 1 2014 The MPN Research Foundation and The Leukemia & Lymphoma Society (LLS) are proud to announce that ten new research projects will receive funding through their collaboration, renamed MPN Challenge™ in 2014. Winners of these one year grants focus on five areas, selected during 2013’s MFC Forum meeting of academia and industry convened… Read More »2014 MPN CHALLENGE GRANTS AWARD $1 MILLION IN RESEARCH FUNDING
June 23, 2014 The Stem Cell Physiopathology group at the CNIC (the Spanish National Cardiovascular Research Center), led by Dr. Simón Méndez–Ferrer has shown that the micro-environment of the bone marrow is a good target for therapeutic options for people with myeloproliferative neoplasms. Click here for the letter, recently published in Nature, or click here for… Read More »2014 CNIC DISCOVERS EXPANDED ROLE OF BONE MARROW MICRO-ENVIRONMENT FOR MPNS
June 12, 2014 Geron Corp. announced today that the FDA has removed the partial clinical hold on its clinical trial of imetelstat in myelofibrosis. The hold for polycythemia vera and essential thrombocythemia remails. Cick here for the full story. Previous reports on Imetelstat: Geron’s Imetelstat put on partial clinical hold for MF trials Telomerase Inhibitor Imetelstat… Read More »FDA REMOVES HOLD ON IMETELSTAT TRIALS IN MF
June 4, 2014 Haematologica recently published a thought-provoking article by Drs. John Mascarenhas and Ronald Hoffman of Mt. Sinai, Dr. Ruben Mesa of the Mayo Clinic, Scottsdale, and Dr. Josef Prchal of the University of Utah, (Optimal therapy for polycythemia vera and essential thrombocythemia can only be determined by the completion of randomized clinical trials)… Read More »THE CRITICAL IMPORTANCE OF CLINICAL TRIALS
June 4, 2014 Haematologica recently published a thought-provoking article by Drs. John Mascarenhas and Ronald Hoffman of Mt. Sinai, Dr. Ruben Mesa of the Mayo Clinic, Scottsdale, and Dr. Josef Prchal of the University of Utah, (Optimal therapy for polycythemia vera and essential thrombocythemia can only be determined by the completion of randomized clinical trials)… Read More »THE CRITICAL IMPORTANCE OF CLINICAL TRIALS
May 21, 2014 MPN Advocacy and Education International is searching for Vietnam Veterans who were exposed to Agent Orange and now have a diagnosis of Myelofibrosis, Polycythemia Vera, or Essential Thrombocythemia (Myeloproliferative Neoplasms-MPNs). This information will be collected in an attempt to add myeloproliferative neoplasms to the US Department of Veterans Affairs ‘presumptive’ list of conditions… Read More »STUDY ON VIETNAM VETERANS WITH MPNS
This ride is in memory of the late Al Bolea who lost his gallant fight against Myelofibrosis on September 23, 2005. Al was the co-founder of the Charles River Wheelmen (CRW) and had a profound effect on the people around him. He showed them the importance of valuing and welcoming each person; that riding is… Read More »ANNUAL AL BOLEA MEMORIAL RIDE
